Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Connexin (Gap Junction Protein) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Connexin (Gap Junction Protein) Products under Development by Stage of Development | 7 | 1 |
| Connexin (Gap Junction Protein) Products under Development by Therapy Area | 8 | 1 |
| Connexin (Gap Junction Protein) Products under Development by Indication | 9 | 1 |
| Connexin (Gap Junction Protein) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Connexin (Gap Junction Protein) Products under Development by Companies | 12 | 2 |
| Connexin (Gap Junction Protein) Products under Development by Universities/Institutes | 14 | 2 |
| Connexin (Gap Junction Protein) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Connexin (Gap Junction Protein) Companies Involved in Therapeutics Development | 23 | 2 |
| Theranexus SAS | 23 | 1 |
| Vichem Chemie Research Ltd. | 24 | 1 |
| Connexin (Gap Junction Protein) Drug Profiles | 25 | 8 |
| (flecainide acetate + modafinil) Drug Profile | 25 | 2 |
| CODA-001 Drug Profile | 27 | 2 |
| JM-2 Drug Profile | 29 | 1 |
| Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy Drug Profile | 30 | 1 |
| THN-01 Drug Profile | 31 | 1 |
| VID-45110 Drug Profile | 32 | 1 |
| Connexin (Gap Junction Protein) Dormant Projects | 33 | 2 |
| Connexin (Gap Junction Protein) Discontinued Products | 35 | 1 |
| Connexin (Gap Junction Protein) Featured News &Press Releases | 36 | 6 |
| May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness | 36 | 1 |
| Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep | 37 | 1 |
| Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA) | 37 | 1 |
| Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies | 38 | 1 |
| Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers | 39 | 1 |
| May 25, 2010: CoDa Therapeutics Achieves Positive Results From Phase II Efficacy Study Of NEXAGON In Chronic Venous Leg Ulcers | 39 | 1 |
| May 11, 2009: CoDa Therapeutics Receives Orphan Drug Designation For Nexagon For The Treatment Of Persistent Corneal Epithelial Defects | 40 | 2 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |